{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:32:42Z","timestamp":1786361562982,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Prostate cancer is the most common solid tumor in males, with a significant incidence worldwide. PSA screening and digital rectal examination are standard screening methods, yet some patients present with advanced disease because of delayed detection. We present the case of locally advanced prostate cancer presenting with large pelvic lymphadenopathy as a unique presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>A 65-year-old man presented with lower urinary tract symptoms and a significantly elevated PSA of 226\u00a0ng\/mL. Physical examination revealed a large, non-tender pelvic mass. Multiparametric MRI revealed a large PIRADS 5 lesion in the prostate (5.6 \u00d7 3.6 cm) with extensive invasion, including seminal vesicles and the right posterior bladder wall. PET PSMA scan showed extensive regional lymph node involvement but no distant metastasis. Prostate biopsy showed Gleason 8 (4\u00a0+\u00a04) adenocarcinoma. The patient was classified as having Stage IVa (T3bN1M0) prostate cancer and underwent treatment with androgen deprivation therapy (ADT), androgen receptor pathway inhibitors, and intensity-modulated radiotherapy (IMRT), targeting the prostate and pelvic lymph nodes. The patient achieved a PSA at 6\u00a0months 1.5\u00a0ng\/mL, and &lt;0.006\u00a0ng\/mL at 15\u00a0months with significant regression of the pelvic mass and lymphadenopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">De novo<\/jats:italic>\n                      metastatic prostate cancer is more prevalent in developing countries, likely due to delayed detection and under-screening. Our case is unique in presenting a pelvic mass as the initial manifestation of locally advanced prostate cancer. While existing guidelines do not subclassify stage IVa prostate cancer patients based on size of the lymph node, our case highlights the importance of personalized treatment strategies based on lymph node involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case presents a unique manifestation of prostate cancer as a large pelvic mass. It emphasizes the importance of early screening and advanced treatment strategies to enhance patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004510","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:01:31Z","timestamp":1766059291000},"page":"1867-1876","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advanced prostate cancer presenting as bulky loco-regional disease without distant metastasis: a case report with review of the management \u2013 What is the optimal treatment?"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6061-6040","authenticated-orcid":false,"given":"Oussama G.","family":"Nasrallah","sequence":"first","affiliation":[{"name":"Division of Urology and Renal Transplantion, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2538-6704","authenticated-orcid":false,"given":"Jana H.","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Youssef","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Khouzami","sequence":"additional","affiliation":[{"name":"Department of Radiology, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9985-5372","authenticated-orcid":false,"given":"Raja B.","family":"Khauli","sequence":"additional","affiliation":[{"name":"Division of Urology and Renal Transplantion, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon"},{"name":"Section of Urology, Carle-Illinois College of Medicine (CIMED), Urbana-Champaign, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"R1-20260810","first-page":"12\u201349","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"1067\u201396","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"705\u201307","DOI":"10.1001\/jamaoncol.2016.5465","article-title":"Increase in prostate cancer distant metastases at diagnosis in the United States","volume":"3","author":"Hu","year":"2017","journal-title":"JAMA Oncol"},{"key":"R4-20260810","first-page":"1901\u201313","article-title":"Screening for prostate cancer: US preventive services task force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"Jama"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"418\u201323","DOI":"10.4103\/UA.UA_47_20","article-title":"High rates of advanced prostate cancer in the middle east: analysis from a tertiary care center","volume":"13","author":"Daher","year":"2021","journal-title":"Urol Ann"},{"key":"R7-20260810","first-page":"2","article-title":"Revised surgical CAse REport (SCARE) guideline: an update for the Age of Artificial Intelligence","author":"Ahmed","year":"2025","journal-title":"Prem J Sci"},{"key":"R8-20260810","doi-asserted-by":"crossref","first-page":"2931\u201338","DOI":"10.1002\/cncr.31384","article-title":"Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts","volume":"124","author":"Helgstrand","year":"2018","journal-title":"Cancer"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"505\u201311","DOI":"10.1016\/j.clgc.2015.05.010","article-title":"Prostate cancer in the arab world: a view from the inside","volume":"13","author":"Hilal","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"R10-20260810","doi-asserted-by":"crossref","first-page":"407\u201321","DOI":"10.1007\/s44197-023-00103-6","article-title":"Global burden of prostate cancer and association with socioeconomic status, 1990-2019: a systematic analysis from the global burden of disease study","volume":"13","author":"Zhang","year":"2023","journal-title":"J Epidemiol Glob Health"},{"key":"R11-20260810","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.3390\/cancers15204945","article-title":"De novo metastatic prostate cancer: are we moving toward a personalized treatment?","volume":"15","author":"Piombino","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R12-20260810","doi-asserted-by":"crossref","first-page":"352\u201360","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20260810","doi-asserted-by":"crossref","first-page":"447\u201360","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"R14-20260810","first-page":"121\u201331","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis Ian","year":"2019","journal-title":"N Engl J Med"},{"key":"R15-20260810","first-page":"13\u201324","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20260810","first-page":"1132\u201342","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith Matthew","year":"2022","journal-title":"N Engl J Med"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"1080\u201387","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R18-20260810","doi-asserted-by":"crossref","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"R19-20260810","first-page":"243\u201344","article-title":"Phase III study for local or locally advanced prostate cancer: randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90\/15 of the AUO","volume":"56","author":"Rexer","year":"2017","journal-title":"Urologe A"},{"key":"R20-20260810","article-title":"PROTEUS: a randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)","volume":"37","author":"Taplin","journal-title":"J Clin Oncol"},{"key":"R21-20260810","doi-asserted-by":"crossref","first-page":"508\u201318","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"R22-20260810","doi-asserted-by":"crossref","first-page":"2091\u2013102","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"R23-20260810","first-page":"395\u2013405","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"R24-20260810","doi-asserted-by":"crossref","first-page":"1419\u201323","DOI":"10.2169\/internalmedicine.47.1124","article-title":"Eosinophilic pneumonia and thoracic metastases as an initial manifestation of prostatic carcinoma","volume":"47","author":"Ishiguro","year":"2008","journal-title":"Intern Med"},{"key":"R25-20260810","first-page":"1737\u201340","article-title":"Nonbacterial thrombotic endocarditis as the initial presentation of prostate cancer- a case report","volume":"69","author":"Khan","year":"2019","journal-title":"J Pak Med Assoc"},{"key":"R26-20260810","article-title":"Stauffer syndrome as the initial presentation of advanced metastatic prostate cancer","volume":"15","author":"Khanal","year":"2023","journal-title":"Cureus"},{"key":"R27-20260810","first-page":"562\u201365","article-title":"Blue toe syndrome as an initial manifestation of metastatic prostate cancer: a case report with literature review","volume":"43","author":"Vignes","year":"2022","journal-title":"Rev Med Interne"},{"key":"R28-20260810","first-page":"75\u201378","article-title":"Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer","volume":"44","author":"\u00c7ulpan","year":"2018","journal-title":"Turk J Urol"},{"key":"R29-20260810","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0090-4295(02)02269-0","article-title":"Prostate adenocarcinoma presenting with inguinal lymphadenopathy","volume":"61","author":"Huang","year":"2003","journal-title":"Urology"},{"key":"R30-20260810","doi-asserted-by":"crossref","first-page":"96\u201397","DOI":"10.5173\/ceju.2012.02.art11","article-title":"A case of metastatic prostate adenocarcinoma to an inguinal lymph node","volume":"65","author":"Komeya","year":"2012","journal-title":"Cent European J Urol"},{"key":"R31-20260810","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.ijscr.2021.105889","article-title":"Left axillary lymphadenopathy as initial presentation of metastatic prostate cancer: a rare case report","volume":"82","author":"Mremi","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"R32-20260810","first-page":"840\u201344","article-title":"Presentation of prostate carcinoma with cervical lymphadenopathy: report of three cases","volume":"27","author":"Wang","year":"2004","journal-title":"Chang Gung Med J"},{"key":"R33-20260810","first-page":"7301284","article-title":"Solitary abdominal wall lymph node recurrence in prostate cancer patient with dramatic prostate-specific antigen decrease following metastasectomy","volume":"2023","author":"Williams","year":"2023","journal-title":"Case Rep Urol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:02:50Z","timestamp":1786359770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004510","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"2025-04-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}